Innoviva
INVA
21.06
+0.23
+1.10%
Innoviva
US · INVA
#2990 by market cap
Listed 1970
21.06
+0.23
+1.10%
Live - 5344 symbols - heartbeat 221s ago
· 2026-10-08 04:35
Pre-market
21.52
+2.20%
After-hours
21.06
0.00%
Overnight
21.06
0.00%
- Market cap
- 1.52B
- P/E (TTM)i
- 4.89
- P/Bi
- 1.23
- EPSi
- 3.30
- Div yieldi
- 0.00%
- 52W posi
- 53%
Reader sentiment
Are you bullish or bearish on INVA?
Anonymous reader poll. Unscientific, not investment advice.
About Innoviva
Innoviva, Inc. engages in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.
- Founded
- 1996
- CEO
- Mr. Pavel Raifeld
- Employees
- 159
- Headquarters
- Burlingame, California, United States of America
- Fiscal year end
- 12-31
- Website
- inva.com
Company profile
- Exchange
- US
- Symbol
- INVA
- Market-cap rank
- #2990
- Listing date
- 1970-01-01
- Market cap
- 1.52B
- Float cap
- 1.42B
- Shares out
- 72.25M
- Float shares
- 67.65M
Sectors & themes
Quote time 2026-10-08 04:35:24 · For reference only, not investment advice and not tailored to your situation.